Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 12 studies. IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants DAIDS Number 30020 Research Area Therapeutics Study Status Closed to Follow Up P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT DAIDS Number 10770 Research Area Mother to child transmission Study Status Concluded P1071: CCR5 Vicriviroc (SCH-417690) DAIDS Number 10634 Research Area N/A Study Status Concluded P1070: EFV in HIV-infected and HIV/TB Co-infected Subjects DAIDS Number 10633 Research Area Treatment Study Status Concluded P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded P1032: Prevention of Development of Nevirapine-Resistance Mutations in Postpartum Women DAIDS Number 10137 Research Area Other Study Status Concluded P1026S: PK in Pregnancy DAIDS Number Therapeutics Research Area Treatment Study Status Closed to Follow Up Pagination Current page 1 Page 2 Next page Next
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants DAIDS Number 30020 Research Area Therapeutics Study Status Closed to Follow Up
P1081: 3 Regimens for HIV Infected Women initiating ARV regimens for PMTCT DAIDS Number 10770 Research Area Mother to child transmission Study Status Concluded
P1070: EFV in HIV-infected and HIV/TB Co-infected Subjects DAIDS Number 10633 Research Area Treatment Study Status Concluded
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded
P1032: Prevention of Development of Nevirapine-Resistance Mutations in Postpartum Women DAIDS Number 10137 Research Area Other Study Status Concluded
P1026S: PK in Pregnancy DAIDS Number Therapeutics Research Area Treatment Study Status Closed to Follow Up
